Overview

Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder

Status:
Completed

Trial end date:
2003-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to better understand the treatment outcomes of extended-release methylphenidate and atomoxetine in children with attention-deficit hyperactivity disorder (ADHD) as evaluated by physicians and parents in a community setting.

Phase:

Phase 4

Details

Lead Sponsor:

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Treatments:

Atomoxetine Hydrochloride
Methylphenidate